Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Invitrogen

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 5 July 1996:
Vol. 273. no. 5271, pp. 109 - 112
DOI: 10.1126/science.273.5271.109
Prev | Table of Contents | Next

Reports

Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice

Henry T. Lau, * Ming Yu, Adriano Fontana, Christian J. Stoeckert Jr.

Allogeneic transplantation of islets of Langerhans was facilitated by the cotransplantation of syngeneic myoblasts genetically engineered to express the Fas ligand (FasL). Composite grafting of allogeneic islets with syngeneic myoblasts expressing FasL protected the islet graft from immune rejection and maintained normoglycemia for more than 80 days in mice with streptozotocin-induced diabetes. Graft survival was not prolonged with composite grafts of unmodified myoblasts or Fas-expressing myoblasts. Islet allografts transplanted separately from FasL-expressing myoblasts into the contralateral kidney were rejected, as were similarly transplanted third-party thyroid allografts. Thus, the FasL signal provided site- and immune-specific protection of islet allografts.

H. T. Lau and M. Yu, Department of Pediatric Surgery, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
A. Fontana, Department of Internal Medicine, Section of Clinical Immunology, University Hospital of Zurich, Haldeliweg 4, CH-8044 Zurich, Switzerland.
C. J. Stoeckert Jr., Department of Hematology, Abramson Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
* To whom correspondence should be addressed at Department of Pediatric Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Induction of Tolerance to Cardiac Allografts Using Donor Splenocytes Engineered to Display on Their Surface an Exogenous Fas Ligand Protein.
E. S. Yolcu, X. Gu, C. Lacelle, H. Zhao, L. Bandura-Morgan, N. Askenasy, and H. Shirwan (2008)
J. Immunol. 181, 931-939
   Abstract »    Full Text »    PDF »
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.
C. Schutz, M. Fleck, A. Mackensen, A. Zoso, D. Halbritter, J. P. Schneck, and M. Oelke (2008)
Blood 111, 3546-3552
   Abstract »    Full Text »    PDF »
Cytopiloyne, a Polyacetylenic Glucoside, Prevents Type 1 Diabetes in Nonobese Diabetic Mice.
C. L.-T. Chang, S.-L. Chang, Y.-M. Lee, Y.-M. Chiang, D.-Y. Chuang, H.-K. Kuo, and W.-C. Yang (2007)
J. Immunol. 178, 6984-6993
   Abstract »    Full Text »    PDF »
Biological and biomaterial approaches for improved islet transplantation..
A. S. Narang and R. I. Mahato (2006)
Pharmacol. Rev. 58, 194-243
   Abstract »    Full Text »    PDF »
ProtExTM: A Novel Technology to Display Exogenous Proteins on the Cell Surface for Immunomodulation.
N. P. SINGH, E. S. YOLCU, N. ASKENASY, and H. SHIRWAN (2005)
Ann. N.Y. Acad. Sci. 1056, 344-358
   Abstract »    Full Text »    PDF »
Corneal graft rejection occurs despite Fas ligand expression and apoptosis of infiltrating cells.
K A Williams, S D Standfield, J R Smith, and D J Coster (2005)
Br. J. Ophthalmol. 89, 632-638
   Abstract »    Full Text »    PDF »
Induction of tolerance using Fas ligand: a double-edged immunomodulator.
N. Askenasy, E. S. Yolcu, I. Yaniv, and H. Shirwan (2005)
Blood 105, 1396-1404
   Abstract »    Full Text »    PDF »
Fas Ligand Is Required for Resolution of Granulomatous Experimental Autoimmune Thyroiditis.
Y. Wei, K. Chen, G. C. Sharp, and H. Braley-Mullen (2004)
J. Immunol. 173, 7615-7621
   Abstract »    Full Text »    PDF »
Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance.
O. Bohana-Kashtan and C. I. Civin (2004)
Stem Cells 22, 908-924
   Abstract »    Full Text »    PDF »
Complete Loss of Fas Ligand Gene Causes Massive Lymphoproliferation and Early Death, Indicating a Residual Activity of gld Allele.
S. Karray, C. Kress, S. Cuvellier, C. Hue-Beauvais, D. Damotte, C. Babinet, and M. Levi-Strauss (2004)
J. Immunol. 172, 2118-2125
   Abstract »    Full Text »    PDF »
Display of Fas Ligand Protein on Cardiac Vasculature as a Novel Means of Regulating Allograft Rejection.
N. Askenasy, E. S. Yolcu, Z. Wang, and H. Shirwan (2003)
Circulation 107, 1525-1531
   Abstract »    Full Text »    PDF »
Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo.
S. Buonocore, F. Paulart, A. Le Moine, M. Braun, I. Salmon, S. Van Meirvenne, K. Thielemans, M. Goldman, and V. Flamand (2003)
Blood 101, 1469-1476
   Abstract »    Full Text »    PDF »
Inhibition of Metalloproteinase Cleavage Enhances the Cytotoxicity of Fas Ligand.
P. G. Knox, A. E. Milner, N. K. Green, A. G. Eliopoulos, and L. S. Young (2003)
J. Immunol. 170, 677-685
   Abstract »    Full Text »    PDF »
Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation.
K. A. Whartenby, E. E. Straley, H. Kim, F. Racke, V. Tanavde, K. S. Gorski, L. Cheng, D. M. Pardoll, and C. I. Civin (2002)
Blood 100, 3147-3154
   Abstract »    Full Text »    PDF »
Membrane Fas Ligand Activates Innate Immunity and Terminates Ocular Immune Privilege.
M. S. Gregory, A. C. Repp, A. M. Holhbaum, R. R. Saff, A. Marshak-Rothstein, and B. R. Ksander (2002)
J. Immunol. 169, 2727-2735
   Abstract »    Full Text »    PDF »
Immune escape of tumors: apoptosis resistance and tumor counterattack.
F. H. Igney and P. H. Krammer (2002)
J. Leukoc. Biol. 71, 907-920
   Abstract »    Full Text »    PDF »
Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells.
H. Matsue, K. Matsue, M. Kusuhara, T. Kumamoto, K. Okumura, H. Yagita, and A. Takashima (2001)
Blood 98, 3465-3472
   Abstract »    Full Text »    PDF »
Regulation of Fas Ligand Expression by Estradiol and Progesterone in Human Endometrium.
B. Selam, U. A. Kayisli, N. Mulayim, and A. Arici (2001)
Biol Reprod 65, 979-985
   Abstract »    Full Text »    PDF »
Transgenic Expression of CD95 Ligand on Thyroid Follicular Cells Confers Immune Privilege upon Thyroid Allografts.
L. Tourneur, B. Malassagne, F. Batteux, M. Fabre, S. Mistou, E. Lallemand, P. Lores, and G. Chiocchia (2001)
J. Immunol. 167, 1338-1346
   Abstract »    Full Text »    PDF »
Fas Ligand Overexpression on Allograft Endothelium Inhibits Inflammatory Cell Infiltration and Transplant-Associated Intimal Hyperplasia.
M. Sata, Z. Luo, and K. Walsh (2001)
J. Immunol. 166, 6964-6971
   Abstract »    Full Text »    PDF »
CD95 Ligand-Expressing Tumors Are Rejected in Anti-Tumor TCR Transgenic Perforin Knockout Mice.
C. K. Behrens, F. H. Igney, B. Arnold, P. Moller, and P. H. Krammer (2001)
J. Immunol. 166, 3240-3247
   Abstract »    Full Text »    PDF »
Opposing Effects of Transmembrane and Soluble Fas Ligand Expression on Inflammation and Tumor Cell Survival.
A. M. Hohlbaum, S. Moe, and A. Marshak-Rothstein (2000)
J. Exp. Med. 191, 1209-1220
   Abstract »    Full Text »    PDF »
CTLA4Ig Gene Transfer Prolongs Survival and Induces Donor-Specific Tolerance in a Rat Renal Allograft.
S. TOMASONI, N. AZZOLLINI, F. CASIRAGHI, M. C. CAPOGROSSI, G. REMUZZI, and A. BENIGNI (2000)
J. Am. Soc. Nephrol. 11, 747-752
   Abstract »    Full Text »    PDF »
Dendritic Cells Genetically Engineered to Express Fas Ligand Induce Donor-Specific Hyporesponsiveness and Prolong Allograft Survival.
W.-P. Min, R. Gorczynski, X.-Y. Huang, M. Kushida, P. Kim, M. Obataki, J. Lei, R. M. Suri, and M. S. Cattral (2000)
J. Immunol. 164, 161-167
   Abstract »    Full Text »    PDF »
Induction of Allograft Tolerance in the Absence of Fas-Mediated Apoptosis.
X. C. Li, Y. Li, I. Dodge, A. D. Wells, X. X. Zheng, L. A. Turka, and T. B. Strom (1999)
J. Immunol. 163, 2500-2507
   Abstract »    Full Text »    PDF »
Genetically Engineered Pancreatic {beta}-Cell Lines for Cell Therapy of Diabetes.
S. EFRAT (1999)
Ann. N.Y. Acad. Sci. 875, 286-293
   Abstract »    Full Text »    PDF »
Crosstalk Between Keratinocytes and T Lymphocytes via Fas/Fas Ligand Interaction: Modulation by Cytokines.
R. Arnold, M. Seifert, K. Asadullah, and H. D. Volk (1999)
J. Immunol. 162, 7140-7147
   Abstract »    Full Text »    PDF »
Induction of Antitumor Immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma Neuro-2a Cells.
M. Shimizu, A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa (1999)
J. Immunol. 162, 7350-7357
   Abstract »    Full Text »    PDF »
Placental Fas Ligand Expression Is a Mechanism for Maternal Immune Tolerance to the Fetus.
S. W. Kauma, T. F. Huff, N. Hayes, and A. Nilkaeo (1999)
J. Clin. Endocrinol. Metab. 84, 2188-2194
   Abstract »    Full Text »
Constitutive Fas Ligand Gene Transcription in Sertoli Cells Is Regulated By Sp1.
R. F. McClure, C. J. Heppelmann, and C. V. Paya (1999)
J. Biol. Chem. 274, 7756-7762
   Abstract »    Full Text »    PDF »
Soluble Fas Ligand Is Chemotactic for Human Neutrophilic Polymorphonuclear Leukocytes.
L. Ottonello, G. Tortolina, M. Amelotti, and F. Dallegri (1999)
J. Immunol. 162, 3601-3606
   Abstract »    Full Text »    PDF »
Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity.
A. Morelli, A. Larregina, J Smith-Arica, R. Dewey, T. Southgate, B Ambar, A Fontana, M. Castro, and P. Lowenstein (1999)
J. Gen. Virol. 80, 571-583
   Abstract »
CD8alpha + and CD8alpha - Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo.
R. Maldonado-Lopez, T. De Smedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J. Urbain, and M. Moser (1999)
J. Exp. Med. 189, 587-592
   Abstract »    Full Text »    PDF »
Induction of Specific T Cell Tolerance by Fas Ligand- Expressing Antigen-Presenting Cells.
H.-g. Zhang, X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C. K. Edwards, H. Bluethmann, J. D. Mountz, and T. Zhou (1999)
J. Immunol. 162, 1423-1430
   Abstract »    Full Text »    PDF »
Induction of Immunologic Tolerance for Transplantation.
A. A. ROSSINI, D. L. GREINER, and J. P. MORDES (1999)
Physiol Rev 79, 99-141
   Abstract »    Full Text »    PDF »
Gene transfer in the kidney.
V. R. Kelley and V. P. Sukhatme (1999)
Am J Physiol Renal Physiol 276, F1-F9
   Abstract »    Full Text »    PDF »
Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand.
F. Batteux, L. Tourneur, H. Trebeden, J. Charreire, and G. Chiocchia (1999)
J. Immunol. 162, 603-608
   Abstract »    Full Text »    PDF »
Immunotherapy of B-Cell Lymphoma With CD3x19 Bispecific Antibodies: Costimulation via CD28 Prevents "Veto" Apoptosis of Antibody-Targeted Cytotoxic T Cells.
P. T. Daniel, A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dorken, and A. Pezzutto (1998)
Blood 92, 4750-4757
   Abstract »    Full Text »    PDF »
Regulation of the Proinflammatory Effects of Fas Ligand (CD95L).
J. Chen, Y. Sun, and G. J. Nabel (1998)
Science 282, 1714-1717
   Abstract »    Full Text »
Cutting Edge: Chemotactic Activity of Soluble Fas Ligand Against Phagocytes.
K.-i. Seino, K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura (1998)
J. Immunol. 161, 4484-4488
   Abstract »    Full Text »    PDF »
Application of a Fas Ligand Encoding a Recombinant Adenovirus Vector for Prolongation of Transgene Expression.
H.-G. Zhang, G. Bilbao, T. Zhou, J. L. Contreras, J. Gomez-Navarro, M. Feng, I. Saito, J. D. Mountz, and D. T. Curiel (1998)
J. Virol. 72, 2483-2490
   Abstract »    Full Text »    PDF »
Gene Transfer Into the Donor Heart During Cold Preservation for Heart Transplantation.
S. Gojo, K. Niwaya, S. Taniguchi, K. Nishizaki, and S. Kitamura (1998)
Ann. Thorac. Surg. 65, 647-652
   Abstract »    Full Text »    PDF »
Transcriptional Regulation of the Human FasL Promoter-Enhancer Region.
C. J. Holtz-Heppelmann, A. Algeciras, A. D. Badley, and C. V. Paya (1998)
J. Biol. Chem. 273, 4416-4423
   Abstract »    Full Text »    PDF »
Recent advances: Immunology.
M. Kemeny and M. Peakman (1998)
BMJ 316, 600-603
   Full Text »
Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.
M. Sata, H. Perlman, D. A. Muruve, M. Silver, M. Ikebe, T. A. Libermann, P. Oettgen, and K. Walsh (1998)
PNAS 95, 1213-1217
   Abstract »    Full Text »    PDF »
To Die or Not to Die: An Overview of Apoptosis and Its Role in Disease.
S. W. Hetts (1998)
JAMA 279, 300-307
   Abstract »    Full Text »    PDF »
Gene transfer of Fas ligand induces tumor regression vivo.
H. Arai, D. Gordon, E. G. Nabel, and G. J. Nabel (1997)
PNAS 94, 13862-13867
   Abstract »    Full Text »    PDF »
Immune Response and Myoblasts That Express Fas Ligand.
S. Kang, A. Hofmann, D. Le, M. L. Springer, P. G. Stock, H. M. Blau;, H. T. Lau, and C. J. Stoeckert; (1997)
Science 278, 1322-1324
   Full Text »
Reactive Oxygen Intermediates Are Involved in the Induction of CD95 Ligand mRNA Expression by Cytostatic Drugs in Hepatoma Cells.
H. Hug, S. Strand, A. Grambihler, J. Galle, V. Hack, W. Stremmel, P. H. Krammer, and P. R. Galle (1997)
J. Biol. Chem. 272, 28191-28193
   Abstract »    Full Text »    PDF »
Fas-Fas Ligand-Based Interactions Between Tumor Cells and Tumor-Specific Cytotoxic T Lymphocytes: A Lethal Two-Way Street.
A. Zeytun, M. Hassuneh, M. Nagarkatti, and P. S. Nagarkatti (1997)
Blood 90, 1952-1959
   Abstract »    Full Text »    PDF »
Glucose-Stimulated Genes and Prospects of Gene Therapy for Type I Diabetes.
D. Mitanchez, B. Doiron, R. Chen, and A. Kahn (1997)
Endocr. Rev. 18, 520-540
   Abstract »    Full Text »    PDF »
Characterization of Fas (Apo-1, CD95)-Fas Ligand Interaction.
P. Schneider, J.-L. Bodmer, N. Holler, C. Mattmann, P. Scuderi, A. Terskikh, M. C. Peitsch, and J. Tschopp (1997)
J. Biol. Chem. 272, 18827-18833
   Abstract »    Full Text »    PDF »
Proteasome regulation of activation-induced T cell death.
H. Cui, K. Matsui, S. Omura, S. L. Schauer, R. A. Matulka, G. E. Sonenshein, and S.-T. Ju (1997)
PNAS 94, 7515-7520
   Abstract »    Full Text »    PDF »
Fas-ligand: Privilege and peril.
D. R. Green and C. F. Ware (1997)
PNAS 94, 5986-5990
   Full Text »    PDF »
The Fas System Is a Key Regulator of Germ Cell Apoptosis in the Testis.
J. Lee, J. H. Richburg, S. C. Younkin, and K. Boekelheide (1997)
Endocrinology 138, 2081-2088
   Abstract »    Full Text »    PDF »
Transgenic expression of CD95 ligand on islet beta  cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
J. Allison, H. M. Georgiou, A. Strasser, and D. L. Vaux (1997)
PNAS 94, 3943-3947
   Abstract »    Full Text »    PDF »
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape.
M. Hahne, D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. (1996)
Science 274, 1363-1366
   Abstract »    Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)